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Abstract: Vessels respond to injury by a healing process that includes the
development of neointima. Stenosis secondary to neointima formation is the
main cause of failure following arterial reconstructions. Vessel wall ho-
meostasis is regulated by proinflammatory cytokines that affect smooth
muscle cell proliferation, growth, migration, and death. We assessed the
hypothesis that naringenin, a flavinoid possessing anti-inflammatory, antiox-
idant, and antiproliferative activities, reduces neointimal hyperplasia (NIH)
following vascular injury.
Arterial injury was created by interposition grafting of autologous right
superficial epigastric vein graft into the right femoral artery (FA) in 48 male
Sprague-Dawley rats. Following injury, the rats were divided into 4 groups
(n  12). Two groups were treated with naringenin (100 mg/kg intraperito-
neal q daily) for 2 and 4 weeks each while 2 control groups received normal
saline for the same durations. For Sham group (n  10), the FA and vein
were isolated without any additional procedure. Rats were killed at the end
of treatment regimen in all groups, and FAs were harvested. Thickness of
intima was measured in histologic sections, and levels of platelet derived
growth factor (PDGF)-BB, TNF, and Ki67 labeling index (Ki67 LI) were
quantified in immunohistochemical analyses to assess the amount of NIH and
mechanisms underlying its formation.
Although there was no significant difference between the groups at 2
weeks, neointima thickness was lower in the naringenin treated group at 4
weeks (23.7  2.3 vs. 35.6  2.6 m in control group; P  0.001). The
levels of PDGF-BB, and TNF were lower in naringenin treated groups at
both 2 weeks (PDGF-BB 0.21%  0.03% versus 0.39%  0.05% in control
group, P  0.001), TNF (21.2%  0.8% vs. 36.1%  1.9% in control
group, P  0.001) and 4 weeks (PDGF-BB 0.25%  0.03% vs. 0.57% 
0.09% in control group, P  0.001, TNF 25.5%  1.8% vs. 45.0% 
2.9% in control group, P  0.001). Ki67 LI was lower in naringenin treated
groups at 2 weeks (13.9%  2.8% vs. 18.7%  3.7% in control group, P 
0.05), and at 4 weeks (17.5%  2.6% vs. 31.1%  4.7% in control group,
P  0.001), indicating a lower level of cellular proliferation.
Naringenin reduces NIH following arterial reconstruction. This may be
mediated by a decrease in PDGF-BB and TNF levels and the resulting
down-regulation of smooth muscle cells’ migration and proliferation.
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Development of neointima as a part of the healing process inresponse to injury is the main reason of failure in arterial
reconstruction. The incidence of this outcome is as high as 15% 1
year after,1 and 44% 10 years after2 aortocoronary bypass grafting
with autologous saphenous vein grafting. Intimal thickening and
luminal narrowing are also a major cause of failure after coronary
angioplasty,3 femoropopliteal revascularization with autologous sa-
phenous vein or synthetic grafts or transluminal angioplasty.3,4
Recent advances in the understanding of their biology suggest that
endothelial cells play a central role in the development of intimal
hyperplastic response after arterial reconstruction.
The healing process in an arterial reconstruction with a vein
graft involves responses to both surgical trauma,5,6 and adaptation of
the vein to arterial hemodynamic conditions.7
Among several pro-inflammatory cytokines with possible
roles in neointimal hyperplasia, platelet derived growth factor
(PDGF) has diverse effects on different target cells, and has been
implicated in the pathogenesis of arterial vascular disease.8 Tumor
necrosis factor-alpha (TNF), another proinflammatory cytokine, is
locally generated from arterial smooth muscle cells following vas-
cular trauma and is implicated in the pathogenesis of vein graft
neointimal hyperplasia.9,10
Flavinoids are found in seeds, citrus fruits, olive oil, tea, and
red wine and are commonly consumed within the human diet11 in
small amounts (approximately 1 g of flavinoids per day). They have
been reported by many authors to have anti-inflammatory, antialler-
gic, antiviral, and antioxidant effects, and they have also shown the
ability to inhibit tumor cell proliferation.12,13 Because of the pivotal
role of anti-inflammatory medications, researchers14–16 have at-
tempted to identify naturally-occurring, novel biologic components
from plants with potent anti-inflammatory activity. The inhibitory
effects of flavinoids, especially naringenin on TNF, has been
demonstrated in previous studies.17,18 It has also been demonstrated
that naringenin can exert antifibrogenic affects through TGF-
signaling,19 which also has a role in the migration of smooth muscle
cells into the intima.20–22 Considering the activities of naringenin on
pro-inflammatory cytokines and the known roles of these cytokines
on the development of intimal hyperplasia, we designed this study to
examine the influence of naringenin on vein graft intimal hyperpla-
sia.
MATERIALS AND METHODS
Fifty-eight male Sprague-Dawley adult rats, with an age
range of 8 to 10 weeks, were used for the study. The body weights
of the rats ranged from 240 to 310 g. Columbia University Institute
for Animal Care and Use Committee (IACUC) guidelines for the
care and the use of laboratory animals were followed throughout all
steps in this study. The rats were divided into 3 as control, experi-
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mental, and sham groups. Two experiment groups were treated with
naringenin (100 mg/kg intraperitoneal q daily) for 2 and 4 weeks
each, whereas 2 control groups received daily intraperitoneal normal
saline injections for the same durations. No treatment was applied to
the rats in the sham group. Half of the animals in each (experiment,
control, and SHAM) group were killed at 2 weeks and the other half
at 4 weeks. The arterial reconstruction model with autologous vein
grafting was used for the study. For this purpose superficial epigas-
tric vein was interposed to the femoral artery (Fig. 1).
Surgical Procedure
The rats were anesthetized with isoflurane (1%–5%) inhala-
tion. After induction of the general anesthesia, bilateral groin re-
gions were shaved with electric clippers. An incision was made
along the entire length of the right inguinal fold. The lateral aspect
of the incision was retracted firmly, drawing the epigastric vessels
out in a linear course. The superficial epigastric vein was dissected
out from the epigastric fat pad, through its origin from the femoral
vein. A 10-mm segment of the superficial epigastric vein was
harvested. The remaining epigastric fat pad was dissected and
retracted laterally, and the femoral neurovascular bundle was ex-
posed. A 15 to 20 mm tract of the femoral artery (FA), including the
superficial epigastric branch, was dissected free from the underlying
muscle fascia and femoral vein. The surgical field was irrigated with
lidocaine 2% to minimize vasospasm and a latex membrane was
FIGURE 1. A, vascular anatomy of the femoral region; B, Di-
agram of rat interpositional vein graft model. FA, femoral
artery; FV, femoral vein; SE a-v, Superificial epigastric artery
and vein; S a-v, Saphenous artery and vein; P a-v, popliteal
artery and vein.
FIGURE 2. Representative photograph showing a completed
anastomosis for the interpositional vein graft to the femoral
artery. Each square corresponds to 1 mm. Original magnifi-
cation 16.
FIGURE 3. Representative light micrographs of cross section
of interposed graft (hematoxylin and eosin staining) for inti-
mal thickness measurement. Measurements are done by us-
ing the software AxioVision Version 3.1 (Carl Zeiss) in 4 dif-
ferent quadrants and a mean value is obtained for each
vessel. Original magnification 100.
FIGURE 4. Representative light micrographs of cross section
of interposed graft (hematoxylin and eosin staining). A, Con-
trol group at 2 weeks. B, Naringenin group at 2 weeks. C,
Control group at 4 weeks. D, Naringenin group at 4 weeks.
White arrows indicate internal elastic membrane. Bar repre-
sents 100 m. Original magnification 100.
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positioned beneath the vessels. In the control and experimental
groups (n  48), after the proper set-up, the microvascular approxi-
mator clamp (vein approximator clamp 0.4 g/mm2; S&T Marketing
LTD, Neuhausen, Switzerland) was positioned on the FA. A 5 to 7
mm segment of the FA, including the origin of superficial epigastric
artery, was resected. The 10-mm vein graft was interposed to the
defect on FA. A standard end-to-end anastomoses as described by
Ackland23 was performed with 10–0 monofilament nylon suture
material (S&T Marketing LTD), under the magnification of an
OPMI-1 Carl Zeiss operating microscope (Carl Zeiss Inc,
Oberkochen, Germany) (Fig. 2). In the remaining 10 rats, to serve as
the Sham groups, with the same surgical exposure right femoral
neurovascular bundle was isolated, the femoral artery and vein are
dissected free from the surrounding soft tissues and each other. The
skin incision was closed primarily without any additional manipu-
lation to the vascular structures.
Naringenin was purchased from Sigma-Aldrich, Milwau-
kee, WI (T66001). It was dissolved in dimethyl sulfoxide
(DMSO; 102 M).24
Arterial Harvest and Morphometric Analysis
Rats were euthanized 2 and 4 weeks post injury. During the
harvesting procedure the patency of the vessels were checked by the
milking technique as described by Ackland, and recorded. Bilateral
femoral artery segments approximately 1 cm in length were har-
vested, rinsed with saline, and fixed in 4% paraformaldehyde for 24
hours. The specimens were then paraffin embedded and 5-m thick
sections were obtained from the middle portion of the interposed
vein graft, in an equal distance from the anastomosis site in an effort
to eliminate the selection bias. The sections were stained with
hematoxylin and eosin. The intimal thickness was measured using
AxioVision version 3.1 (Carl Zeiss).
To evaluate the effect of naringenin on intimal thickness, the
vessel section was divided into 4 quadrants and, the greatest per-
pendicular distance between the edge of the inner layer of smooth
muscular tunica (SMT) and the inner edge of the intima in each
quadrant was measured, and the mean value for these 4 measure-
ments was calculated (Fig. 3). Two independent blinded examiners
assessed the reproducibility of the measurements.
Immunohistochemistry
Immunohistochemical Staining Technique for TNF
Paraffin sections were deparaffinized with xylene, hydrated
with ethanol, and rinsed in dH2O. Sections are placed in an antigen
retrieval solution (0.01 M citrate buffer, pH 6.0) for 30 minutes in a
microwave oven at 100°C. To block nonspecific binding of
FIGURE 5. Effect of naringenin on intimal
thickness at 2 (A) and 4 (B) weeks, the dis-
tance between the inner intimal surface to
the internal elastic lamina. Values are ex-
pressed as mean  SEM *P  0.05 experi-
ment groups compared with each other.
Annals of Plastic Surgery • Volume 64, Number 1, January 2010 Naringenin Inhibits Neointimal Hyperplasia
© 2009 Lippincott Williams & Wilkins www.annalsplasticsurgery.com | 107
immunoglobulin 10% normal horse serum-blocking solution is ap-
plied for 20 minutes in room temperature (RT). We incubated the
sections in mouse anti-TNF (MP-390, Endogen) diluted 1:150 for
1 hour at room temperature. The sections are rinsed, incubated first
in peroxidase blocking solution for 10 minutes, and than biotinylated
horse antimouse IgG for 30 minutes at room temperature. We used
preformed Avidin: Biotinylated enzyme Complex (VECTASTAIN
ABC kit—Vector Laboratories, Burlingame, CA) as the detection
reagent, for 30 minutes. Sections are incubated in DAB peroxidase
substrate solution (5 minutes) and counterstained with Gill’s hema-
toxylin solution. Following dehydration with ethanol, and cleansing
with xylene, sections are cover slipped with permanent mounting
medium.
Immunohistochemical Staining Technique for Ki-67
Paraffin sections were deparaffinized with xylene, hydrated
with ethanol, and rinsed in dH2O. Sections are placed in an antigen
retrieval solution (0.01 M citrate buffer, pH 6.0) for 30 minutes in a
microwave oven at 100°C. Normal goat serum blocking solution
was used to block nonspecific binding of Ig. Rabbit antihuman Ki67
monoclonal antibody (VP-RM04, Vector Laboratories) in 1:200
dilution for 60 minutes in RT, was used as the primary antibody.
After quenching of endogenous peroxide, sections were incubated in
biotinylated Goat antirabbit IgG. ABC kit was used as the detection
reagent; sections were incubated in DAB solution and counter-
stained with Gill’s hematoxylin solution. The slides were dehydrated
with ethanol, cleansed with xylene and cover slipped with perma-
nent mounting medium.
Immunohistochemical Staining Technique for PDGF-BB
To determine the levels of PDGF-BB, we used goat
antirhPDGF-BB antibody (AF-220-NA, R&D Systems, Minneapo-
lis, MN) and a secondary antigoat IgG antibody. Slides were
deparaffinized and substrate retrieved by boiling in pH 6.0 citrate
buffer. Sections were blocked with 10% goat serum for 20 minutes
and then incubated with primary antibody in 1:150 dilution at RT.
The slides were then rinsed and incubated with the secondary
antigoat antibody for 40 minutes. ABC kit was used as the detection
reagent; sections were incubated in DAB solution and counter-
stained with Gill’s hematoxylin solution. The slides were dehydrated
with ethanol, cleansed with xylene and cover slipped with perma-
nent mounting medium.
Image Capture and Analyses
Sections were observed under Axioplan 2 Imaging micro-
scope (Carl Zeiss). The images were captured by a camera attached
to the microscope (Axiocam, Carl Zeiss) and transferred to a
computer, using software AxioVision Version 3.1 (Carl Zeiss). To
measure the thickness of the intima, cross sectional photomicro-
graphs of interposed graft (hematoxylin and eosin staining) at 100
magnification were captured. To quantify the amount and the dis-
tribution of PDGF-BB, TNF, and Ki67 2 randomly chosen fields at
400 magnification were captured.
Firstly all slides were investigated to examine the quality of
the brown immunopositive staining for PDGF-BB, and blue immu-
nopositive staining for TNF-alpha, as well as typical brown nuclear
staining for Ki-67; the pixel threshold values could be determined by
visual inspection. To overcome possible assessment bias with this
technique, a double-blind design was performed. At 400 magni-
fication 2 randomly chosen areas were sampled and captured, this
time to avoid allocation bias.
To assess the levels of PDGF-BB or TNF activity, tissue
sections were analyzed and measured using Image-Pro Plus
Ver.4.5.1. Software (Media Cybernetics, Silver Spring, MD).
Briefly, this software allows structures to be selected on the basis of
pixel intensity values in a given color channel. Using the free-
form drawing tool in Image-Pro Plus, we selected the areas
stained with IHC method as the areas-of-interest (AOI). A color
file was created that exactly selected the hue, saturation, and
intensity (color coding) which corresponds to the to the expres-
sion level of the measured antigen. Hue, saturation, and intensity
color coding was chosen because this method specifies color by
hue, excludes features that are too light or dark by intensity, but
at the same time allows measurement of the amount of the
specified color by saturation. Areas of interest were enclosed
using the AOI tool and then thresholded, using MeasureCount/
Size . . . Manual Intensity Range selection tool. The results were
reported as “percent area positively stained” (ratio between the
stained area and the AOI).
For the assessments for Ki67, the sections were analyzed
using software AxioVision Version 3.1 (Carl Zeiss). The cells were
judged to be positive when their nuclei contained dark brown
reaction products. The Ki67 labeling index (Ki67 LI) was calculated
as the percentage of Ki67 positive cells among the total number of
cells in the region of interest.25
Statistical Analysis
Data was processed using SPSS Ver.11.5 for Windows (SPSS
Inc, Chicago, IL). One-way ANOVA was performed to compare
groups with different treatments; post hoc analysis was done with
Tukey test, Dunnett t test, or Games-Howell procedure depending
on the homogeneity of variances. The cut-off for significance was
P  0.05.
RESULTS
Vein graft intimal thickening follows a specific time course.
By the end of second week, initially denuded endothelial surface is
completely recovered with endothelial cells. After this time intimal
thickening is exaggerated.26 During the next 2 weeks, the increase in
wall mass is exponential with associated smooth muscle cell prolif-
FIGURE 6. Photomicrographs showing representative cross
sections of interpositional vein grafts. (Immunohistochemical
staining for PDGF-BB). A, Control group at 2 weeks. B, Nar-
ingenin group at 2 weeks. C, Control group at 4 weeks. D,
Naringenin group at 4 weeks. White arrows indicate internal
elastic membrane. Original magnification 400.
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eration and accumulation.26 Based on this time course we evaluated
intimal thickness, levels of PDGF-BB, TNF activity, and Ki67
labeling at 2 weeks and 4 weeks.
In the follow up period, 1 rat from the naringenin treated
group, and 1 rat from the control group died. During the harvesting
procedure vein grafts of 2 rats from control group, and one from the
experimental group was detected to have no patency; these 3 rats
were excluded from the study.
Effect of Naringenin on Neointimal Hyperplasia by
Morphometric Analysis
At 2 weeks, intimal thickness was lower in the naringenin
treated experiment group but the difference was not statistically
significant (14.35  1.6 vs. 14.48  1.9 m in control group, P 
0.987) (Figs. 4, 5A). Both the experimental and control groups
exhibited statistically significant intimal thickness, compared with
Sham group (7.35  1.5 vs. 14.35  1.6 m in experimental group,
P  0.001 and 7.35  1.5 vs. 14.48  1.9 m in control group,
P  0.001).
At 4 weeks, the experimental group was found to have a
reduced intimal thickness compared with controls, (23.69  2.3 vs.
35.64  2.6 m in control group, P  0.001) (Fig. 5B). Both the
experimental (23.69  2.3 vs. 8.78  2.8 m in Sham group, P 
0.001) and control (35.64  2.6 vs. 8.78  2.8 m in Sham group,
P  0.001) groups had increased intimal thickness when compared
with Sham group (Fig. 5B).
Effect of Naringenin on the Level of PDGF-BB
At 2 weeks, the percentage of PDGF-BB labeled area
in controls was significantly greater compared with the naringenin
treated experimental group (0.21%  0.03% vs. 0.39%  0.05% in
controls, P  0.001) (Fig. 6). The percentage of PDGF-BB stained
area both in experimental (0.21%  0.03% vs. 0.12%  0.01% in
Sham, P  0.001) and control (0.39%  0.05% vs. 0.12%  0.01%
in Sham, P  0.001) groups was significantly higher than Sham
group (Fig. 7A).
At 4 weeks, the immunohistochemically labeled area for
PDGF-BB was higher in the control group when compared with the
experimental group (0.57%  0.09% vs. 0.25%  0.02% in exper-
imental group, P  0.001). Sham group had significantly lower
positively labeled percent area with PDGF-BB than both experiment
and control groups (0.09%  0.03% vs. 0.25%  0.02%, in
experimental group, P  0.001, 0.09%  0.03% vs. 0.57% 
0.09%, in control group, P  0.001 (Fig. 7B).
FIGURE 7. Bar graphs for the PDGF ac-
tivity at 2 (A) and 4 (B) weeks. PDGF
activity is expressed as a percentage of
the area positive for PDGF stain/total
area of interest (AOI). Values are ex-
pressed as mean  SEM *P  0.05 ex-
periment groups compared with each
other.
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Effect of Naringenin on the Level of TNF
TNF levels were lower in experimental group when com-
pared with control group at 2 weeks (21.2%  0.8% vs. 36.04% 
1.8%, in control, P  0.001) (Fig. 8). TNF levels in Sham group
(12.5%  1.6%) were lower than both experimental (P  0.001) and
control (P  0.001) groups (Fig. 9A).
At 4 weeks, percent area labeled for TNF, in control
(45.02%  2.8%) group was significantly higher when compared
with experimental (25.5%  1.8%) group (P  0.001). The percent
area labeled in Sham group (11.1%  0.9%) was significantly lower
than both experimental (P  0.001) and control (P  0.001) groups.
(Fig. 9B).
Effect of Naringenin on the Ki67 Labeling Index
At 2 weeks, the control group exhibited significantly higher Ki67
LI (18.7%  3.7%) when compared with experiment (13.9%  2.8%)
group (P  0.030) (Fig. 10). Sham group’s Ki67 LI (6.4%  1.0%) was
significantly lower than both experimental (P  0.001) and control
(P  0.001) groups (Fig. 11A).
At 4 weeks, the experimental group had a significantly lower
Ki67 LI (17.5%  2.3%) when compared with control (31.1% 
4.7%) group (P  0.001). The difference in Sham group Ki67 LI
(7.04%  0.8%) and both control (P  0.001) and experimental
(P  0.001) were statistically significant (Fig. 11B).
FIGURE 8. Photomicrographs showing representative cross
sections of interpositional vein grafts. (Immunohistochemical
staining for TNF alpha). A, Control group at 2 weeks. B, Na-
ringenin group at 2 weeks. C, Control group at 4 weeks. D,
Naringenin group at 4 weeks. White arrows indicate internal
elastic membrane. Original magnification 400.
FIGURE 9. Bar graphs for the TNF-alpha activity
at 2 (A) and 4 (B) weeks. TNF-alpha activity is
expressed as a percentage of the area positive for
TNF-alpha stain/total area of interest (AOI). Val-
ues are expressed as mean  SEM *P  0.05
experiment groups compared with each other.
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DISCUSSION
New information regarding the physiological timeline of
neointimal hyperplasia allows for further understanding about the
specific time and events following vascular injury. Therefore, it
becomes much easier to study potential interventions to minimize
the microscopic damage and thus increase not only graft patency but
patient vitality.
The presence of endothelial cells at the site of damage likely
plays a large role in the injury response mechanism. Because it is at
the interface between the blood and the vessel wall, endothelium is
a potential regulator of arterial wall homeostasis. Endothelial cells
could regulate the underlying cellular growth and regression,27–30 as
they can secrete factors that affect smooth muscle proliferation,
growth, and migration.27,31 These factors are likely present after
vascular injury implicating them as not only a marker but a stimu-
lator of neointimal hyperplasia.
Arterial reconstruction is associated with 2 types of arterial
injury. The first type is mechanical injury of the native vessel due to
dissection of the artery, suture, endarterectomy, thrombectomy, or
luminal angioplasty. The second type of injury is associated with the
implantation of nonarterial structures such as autologous vein graft,
synthetic graft, or any alloplastic material in contact with the arterial
blood flow such as a stent. In this second type of injury, a healing
response is induced to optimize the relationship between the newly
shaped arterial conduit, the surrounding tissues on the adventitial
side,32 and the blood flow on the luminal side.33 As part of the
response, predominantly smooth muscle cells proliferate,34 ex-
tracellular matrix is synthesized and deposited, and graft extrinsic
cells are recruited into the arterializing graft35; forming neoin-
tima composed of smooth muscle cells as well as collagen,
elastin, and proteoglycans.7,36 –38
Furthermore, vein grafts in the arterial circulation develop
intimal thickening, whereas this process does not occur in veins
transposed to venous circulation.39 This suggests that hemodynamic
stress is a major determinant in venous bypass structural changes.39
There is a time course in venous intimal thickening, described in a
rabbit model, in which the external jugular vein is transplanted into
the carotid artery.26 Initially platelets, microthrombi, and leukocytes
adhere mostly to the anastomoses where the endothelium is de-
nuded. In 2 weeks, the denuded surface is completely covered with
new endothelial lining, as the intimal thickening starts to develop.
The functional pathway of the endothelium allows for 2 potential
points of intervention, the regulation of smooth muscle cell migra-
tion and smooth muscle cell proliferation. In this complex process,
evidence of a supporting role for proinflammatory cytokines is
emerging.40–42
In this study, naringenin proved to be an effective treatment
in preventing neointimal hyperplasia. This ability to reduce hyper-
plasia was demonstrated at 4 weeks and not at 2 weeks. This
evidence points to the likely effect of naringenin mainly revolving
around the inhibition of smooth muscle cell proliferation rather than
the early smooth muscle cell migration. This is further demonstrated
in morphometric analysis of the intimal thickness (in 2 week groups,
intimal thickness was lower in the naringenin treated experiment
group but the difference was not statistically significant 14.35  1.6
vs. 14.48  1.9 m in control group, P  0.987, but in 4 weeks the
experimental group was found to have a reduced intimal thickness
compared with controls, 23.69  2.3 vs. 35.64  2.6 m in control
group, P  0.001). To provide even further data about the func-
tional mechanism of naringenin, future experiments could also
include a group in which naringenin is given in the third week.
The stimulatory effect of PDGF on vascular smooth muscle
cells, especially 1 of 3 isoforms, PDGF-BB, is both migration and
proliferation in vitro, and migration in vivo.43 Additionally, PDGF
prevents programmed cell death (apoptosis) in endothelial cells,
which might contribute to the increased number of cells in the
intima.44 The effect of naringenin on PDGF-BB levels was statisti-
cally significant in reducing the presence of this marker at both 2 and
4 weeks. These results demonstrate the ability of naringenin to affect
cellular migration and proliferation. The statistical significance of
the difference between positively stained PDGF levels in the 2
groups grew from 2 to 4 weeks, indicating the continued effect of
naringenin on smooth muscle cell migration and proliferation.
Another marker studied in this project was TNF. TNF has
multiple biologic effects, including induction of the expression of
cell surface adhesion molecules, release of other inflammatory
mediators (particularly IL-1) and induction of endothelial cell
apoptosis. Accelerated functional endothelial recovery was possible
following de-endothelialization, via neutralization of the effects of
free TNF by TNF soluble receptor (TNFsr),45 suggesting a
FIGURE 10. Photomicrographs showing representative cross
sections of interpositional vein grafts. (Immunohistochemical
staining for Ki67). A, Control group at 4 weeks. B, Naringe-
nin group at 4 weeks. White arrows indicate cells that are
positive for Ki67 stain; black arrows indicate internal elastic
membrane. Original magnification 400.
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deleterious role for this cytokine on endothelial cell regrowth.
Inhibition of either the receptor or the release of TNF may prove
advantageous in the prevention of NIH. The presence of naringenin,
in this study, demonstrated just this ability. At both 2 and 4 weeks,
the presence of naringenin significantly reduced the presence of
stained TNF. Once again, the difference increased as time pro-
gressed indicating the affect is likely due to the inhibition of
proliferation rather than migration.
Finally, this study looked at the affect of naringenin on
cellular proliferation. Ki67 is a very important method in detecting
the proliferation of cells. In fact, the levels of Ki7LI are directly
proportional with the staging/prognosis of cancer, due to cancer’s
higher, more aggressive proliferation. In this study, Ki67 is used as
a reliable indicator of smooth muscle cell proliferation in the intima.
As with both of the previously mentioned indicators, levels of Ki67
were significant at both 2 weeks and 4 weeks. The increase in the
difference and significance, along with the known physiology of
Ki67, demonstrate the ability of naringenin to decrease cellular
proliferation.
The flavanoid, Naringenin, demonstrates the ability to act as
a potent inhibitor of neointimal hyperplasia as shown in all aspects
of the results. In nearly all portions of this study, Naringenin was
able to significantly reduce hyperplasia at both 2 and 4 weeks.
However, it must be noted that there was no thickness difference at
2 weeks. This speaks, once again, to the likely mechanism of
Naringenin with respect to NIH. It will be important for future
research to delve into the exact mechanism of Naringenin and its
actions against NIH. Naringenin has demonstrated in this study its
effectiveness in reducing the hyperplasia response due to vascular
injury. More research is certainly needed to completely understand
the actions of this drug along with its interaction with other NIH
inhibitors. It must also be noted that side effects and safety of
Naringenin was not observed in this research, as it was necessary to
first ascertain the potential benefits and potential mechanism of this
drug. Further research in this area is also necessary.
The effectiveness of Naringenin in reducing NIH was
clearly demonstrated in this study. Flavinoids such as this,
represent a potent chemical available for the reduction of this
dangerous response. Though the exact mechanism of Naringenin
is not completely understood, the likely inhibition of smooth
muscle cell proliferation provides an effective tool in the pre-
vention of NIH.
FIGURE 11. Bar graphs for the Ki67 la-
beling index (Ki67 LI) at 2 (A) and 4 (B)
weeks. Ki67 LI was calculated as the
percentage of Ki67 positive cells among
the total number of cells in the region
of interest. Values are expressed as
mean  SEM *P  0.05 experiment
groups compared with each other.
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